Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

Flexible single-tract nephroscopy vs. multi-tract PCNL for complex kidney stones

Official title: Flexible Nephroscopy-Assisted Single-Tract Versus Multi-Tract Percutaneous Nephrolithotomy for Complex Renal Stones: A Prospective, Randomized, Non-Inferiority Trial

Run by Al-Azhar University · NCT07753733 · Data updated 2026-11-12

This randomized trial tests whether a flexible nephroscopy-assisted single-tract PCNL can match the stone-free rate of the standard multi-tract PCNL in people with complex unilateral kidney stones.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment470 (estimated)
SponsorAl-Azhar University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedAugust 13, 2026
Main results expectedJune 30, 2028
Study endsAugust 30, 2028
Registry record updatedSeptember 1, 2026
Trial IDNCT07753733 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–70 with complex unilateral renal stones meeting specific imaging criteria and who are planned for multiple access during surgery.

Probably not a fit

Patients with solitary kidney, high surgical risk (ASA IV+), infection, or stones not meeting inclusion criteria may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with complex unilateral renal stones are randomized to receive either flexible nephroscopy-assisted single-tract PCNL or conventional multi-tract PCNL. The study’s primary goal is to see if the single-tract approach is not worse than the multi-tract approach in achieving a stone-free kidney at 3 months. Secondary outcomes assess operative and fluoroscopy times, blood loss, transfusion needs, length of hospital stay, complications, need for additional procedures, and cost-effectiveness. The analysis will also explore how predictive stone scoring systems relate to outcomes. This is a prospective, parallel-group, non-inferiority trial.

Why it matters

Potential benefit: If successful, patients may experience similar stone clearance with fewer canals, potentially reducing operative risk and recovery time.

How similar studies have gone: Prior approaches with flexible nephroscopy have shown promise, but direct non-inferiority data for single-tract PCNL in complex stones remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18-70 years.

Unilateral complex renal stones defined by one or more of the following: Guy's Stone Score III-IV, S.T.O.N.E. score ≥9, staghorn or partial staghorn calculus, or stones involving at least 3 calyces on NCCT.

Preoperative expectation of multiple accesses by the surgeon.

Written informed consent.

Exclusion Criteria:

Solitary kidney.

Uncorrected coagulopathy.

Active urinary tract infection.

ASA grade IV or higher.

Pregnancy.

Previous ipsilateral PCNL or open renal surgery.

Stones less than 2 cm or simple calyceal stones.

Refusal or inability to comply with follow-up.

\-

Where it's running

  • Department of Urology, Al-Hussein and Sayed Galal University Hospitals, Al-Azhar University
    Cairo, Egypt
    Recruiting

Study contacts

  • Principal investigator: Abul-fotouh Ahmed — Department of Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
  • Study coordinator: Abul-fotouh Ahmed
  • Email: abulfotouhahmed7070@gmail.com
  • Phone: 00201001066756

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.